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1. Introduction 
Graham Hughes described in 1983 a syndrome, characterized by recurrent arterial and 
venous thrombosis, pregnancy morbidity, thrombocytopenia, and the presence of 
antiphospholipid antibodies (aPL), which was named antiphospholipid syndrome [Hughes, 
1983]. Many other features of this syndrome were identified during the time. In present, 
antiphospholipid syndrome is considered a systemic form of autoantibody-induced 
thrombophilia, which involves many organs [Wilson et al., 1999]. 
Antiphospholipid antibodies (aPL) are: lupus anticoagulant (LA), anticardiolipin antibodies 
(aCL), and anti-β2-glycoprotein I antibodies [Cervera et al., 2002]. Classification criteria for the 
antiphospholipid syndrome had been updated by Miyakis et al. in 2006 [Miyakis et al., 2006]. 
Antiphospholipid syndrome was first described in patients with systemic lupus 
erythematosus. Now, it is known that this syndrome may be associated with another 
disorder (autoimmune diseases, malignancies, infections or drugs), or, may be appear alone, 
named as primary antiphospholipid syndrome [Sinico et al., 2010]. 
This disorder may involve any organ in the body, due to vascular thrombosis. The kidney 
involvement represents one of the most important features of this syndrome. Renal 
manifestations reflect the extension of thrombotic process in the kidney vascular bed: main 
renal arteries, intrarenal arteries and arterioles, glomerular capillaries, renal veins 
[Tektonidou et al., 2000; Vlachoyiannopoulos et al., 2001]. Besides the thrombotic lesions, 
glomerulonephritis were described in patients with primary antiphospholipid syndrome, 
too [Nochy et al., 2002; Fakhouri et al., 2003; Sinico et al., 2010]. 
Renal involvement appears in 2.7% of patients with antiphospholipid syndrome [Cervera et 
al., 2002], but the real incidence is greater. The explanations of this underestimated 
incidence are represented by the fact that renal biopsy is a high-risk procedure in patients 
treated with anticoagulants, and, on the other hand, renal manifestations of 
antiphospholipid syndrome are frequently attributed to other conditions, as essential 
hypertension, or, lupus nephritis [Tektonidou, 2009]. In catastrophic antiphospholipid 
syndrome, kidney involvement was reported in 78% of cases [Uthman, Khamashta, 2006]. 
Renal manifestations associated with antiphospholipid syndrome are summarized in table 1 
[Uthman, Khamashta, 2006]. 
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Renal manifestation Main clinical and laboratory findings 
Renal artery lesions  hypertension 
 decreased glomerular filtration rate 
Hypertension  hypertension 
 decreased glomerular filtration rate 
Antiphospholipid syndrome nephropathy  hypertension 
 proteinuria 
 hematuria 
 decreased glomerular filtration rate 
Renal vein thrombosis  proteinuria (even nephrotic syndrome) 
 hematuria 
End stage renal disease/renal transplant  decreased glomerular filtration rate 
 vascular thrombosis of renal allograft 
Table 1. Renal manifestations in antiphospholipid syndrome 
2. Renal artery lesions 
Renal artery lesions are represented by stenosis or occlusion. Renal artery stenosis, 
thrombosis and renal infarction were described by many authors [Asherson et al., 1991; 
Ames et al., 1992; Mandreoli et al., 1992; Godfrey et al., 2000]. The first case of renal artery 
involvement in antiphospholipid syndrome was reported by Ostuni et al. [Ostuni et al., 
1990]. They described the appearance of renal artery thrombosis and hypertension in a 
young female patient with high titers of aCL and a false positive venereal disease research 
laboratory test. Then, Asherson et al. reported the case of young man with primary 
antiphospholipid syndrome, who suddenly developed severe hypertension due to right 
renal artery stenosis [Asherson et al., 1991]. Another patient described by Ames and 
collaborators presented hypertension and oliguria, bilateral renal artery occlusions on 
renal arteriography and high titers of circulating aPL [Ames et al., 1992]. Sangle et al., 
using magnetic resonance angiography, identified that 26% of the aPL-positive patients 
with severe, poorly controlled arterial hypertension had renal artery stenosis, compared 
with 8% in young aPL-negative hypertensive patients [Sangle et al., 2003]. The renal 
artery stenosis in aPL-positive patients has two patterns. In the first, most common, the 
stenosis is smooth, well-delineated, often non-critical, localized distal to the renal artery 
ostium. Another pattern, less common, is localized proximally, occasionally involving the 
aorta [Uthman, Khamashta, 2006; Tektonidou, 2009]. The common features of renal artery 
stenosis are represented by: renovascular hypertension and decrease of glomerular 
filtration rate [Mandreoli, Zuccheli, 1993]. Reno-vascular hypertension in patients with 
antiphospholipid syndrome and inadequate anticoagulation has a progressive evolution, 
leading to the renal impairment function [Sangle et al., 2005]. Based on the thrombotic 
basis of these renal lesions, Sangle et al. recommended that all the hypertensive patients 
with aPL-related renal artery stenosis need to be treated with anticoagulant drugs, 
irrespective of the presence of previous thrombotic events [Sangle et al., 2005]. Renal 
artery thrombosis determines the occurrence of severe hypertension or a worsening of a 
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previously arterial hypertension. In some cases, these patients present pain in lumbar 
area, hematuria, or decreased of renal function. This renal artery disorder is caused by in 
situ thrombosis or embolism from heart valve. Other factors involved in the appearance of 
thrombosis are represented by increased levels of endothelin and accelerated 
atherosclerosis. The complete occlusion of renal arteries leads to renal infarcts. They may 
be symptomatic (uni-, bilateral lumbar pain, hypertension, hematuria, oliguria if the 
lesions are bilateral), or may have a subclinical evolution. In the latter case, the old 
infarcts may be discovered by imagistic methods [Sonpal et al., 1993]. 
Imagistic methods such as renal ultrasonography (including main renal artery Doppler 
ultrasonography), computed tomography, renal scintigraphy, renal angiography, and 
gadolinium enhanced magnetic resonance angiography contribute to the diagnosis and 
severity assessment of the renal arteries lesions [Mandreoli, Zuccheli, 1993; Sangle et al., 
2003]. 
The treatment consists in antihypertensive, anticoagulants and antiplatelets drugs. 
Because the high values of blood pressure have a negative impact on renal function, it is 
reasonable to diminish these values, without worsening the renal function [Asherson et 
al., 1991; Godfrey T et al., 2000; Tektonidou, 2009]. Although the renal arteries stenoses 
are often non-critical, it is recommendable to avoid the use of angiotensin-converting 
enzyme inhibitors and angiotensin receptor blockers in hypertension therapy of these 
patients [D'Cruz, 2009]. But other authors reported a good control of high blood pressure 
with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium 
channel blockers, without worsening the renal function [Godfrey et al., 2000]. Poststenotic 
reduction of renal perfusion pressure stimulates the appearance of high levels of 
angiotensin II, resulting vasoconstriction of the efferent arteriole, which preserves the 
glomerular capillary filtration pressure. Angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers inhibit this compensatory mechanism, and results a 
reduction of glomerular filtration rate. But the reduction of the glomerular filtration rate is 
not specific to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. 
The reduction of high blood pressure may impair the autoregulation of intrarenal 
circulation, and then the renal function declines, irrespective of antihypertensive agents. 
That is why is very important to closely check the renal function after the initiation of 
antihypertensive therapy [Mimran, 1992]. Remondino et al. demonstrated that the oral 
anticoagulation may contribute to the recanalization after bilateral renal artery thrombosis 
with the subsequent normalizing the high blood pressure [Remondino et al., 2000]. The 
beneficial role of oral anticoagulant therapy (INR of 3.0 to 4.5) in control of arterial 
hypertension and improve of the renal function was demonstrated by Sangle et al. A 
value of INR < 3.0 is associated with poorly controlled blood pressure, and deterioration 
of glomerular filtration rate [Sangle et al., 2005]. Other therapeutic methods are: 
thrombolysis, transluminal balloon angioplasty with or without stenting, surgical 
interventions [Rysana et al., 1998; Sangle et al., 2005; Tektonidou, 2009]. 
3. Arterial hypertension 
Hypertension is common in patients with antiphospholipid syndrome. Hughes described in 
1983 the features of arterial hypertension in these patients. He sustained that hypertension 
in patients with antiphospholipid syndrome  often fluctuates, apparently correlating with 
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the severity of the livedo, inferring the relationship between thrombotic renal lesions and 
high blood pressure [Hughes, 1984]. 
The etiology of hypertension in antiphospholipid syndrome is represented by the stenosis or 
occlusion of renal artery, or, by the intrarenal vascular lesions. Cacoub et al. studied the 
kidney lesions in a group of 5 patients with antiphospholipid syndrome and malignant 
hypertension, in the absence of lupus nephritis. These lesions were represented by ischemic 
glomeruli without proliferation, focal intimal fibrosis, and thrombosis [Cacoub et al., 1992]. 
Another study performed by Kincaid-Smith et al., revealed fibrin thrombi in glomeruli and 
in intrarenal arterioles [Kincaid-Smith et al., 1988]. Nochy et al. reported the presence of 
high blood pressure in 93% of the 16 patients with primary antiphospholipid syndrome. In 
some cases, hypertension represented the unique sign of renal involvement in this 
syndrome. In this study, the authors revealed that the causes of hypertension are 
represented by intrarenal vascular lesions: arteriosclerosis, fibrous intimal hyperplasia, 
arterial and arteriolar fibrous, fibrocellular occlusions and thrombotic microangiopathy 
[Nochy et al., 1999]. In 25 patients with severe essential hypertension, Rollino et al. 
identified aPL in 8% of them, a frequency higher than in control population [Rollino et al., 
2004]. High levels of anti-β2-glycoprotein I antibodies were identified by Frostegard et al. in 
73 borderline hypertensive patients [Frostegard et al., 1998]. 
Hypertensive aPL-positive patients had to be extensively investigated: glomerular rate 
filtration, urinary sediment, proteinuria, renal ultrasonography (including Doppler of renal 
arteries, veins, and intrarenal vessels) (fig. 1), renal angiography [Tektonidou, 2009]. 
 
Fig. 1. Increased resistive index (RI) of interlobar renal arteries in hypertensive patient with 
antiphospholipid syndrome 
The objective of the treatment is to obtain reduced blood pressure values in order to 
preserve the renal function. It is achieved by an association between antihypertensive drugs 
and anticoagulants [Nochy et al., 2002; Tektonidou, 2009, Sinico et al., 2010]. 
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4. Antiphospholipid syndrome nephropathy 
The intrarenal vascular lesions associated with antiphospholipid syndrome define 
antiphospholipid syndrome nephropathy. These lesions are represented by: thrombotic 
microangiopathy, arteriosclerosis, fibrous intimal hyperplasia of arterioles and interlobular 
arteries, organized thrombi in arteries and arterioles with or without recanalization, fibrous 
arterial and arteriolar occlusions, focal cortical atrophy [Nochy et al., 1999]. Nochy et al. and 
Tektonidou et al. revealed that the characteristic features of antiphospholipid syndrome 
nephropathy are: arterial hypertension, acute or chronic renal failure, proteinuria and 
microscopic hematuria [Nochy et al., 1999; Tektonidou et al., 2008; Tektonidou, 2009]. 
Systemic hypertension was identified in 93% of studied patients by Nochy et al. The severity 
of hypertension varied from mild to severe, even malignant. Malignant hypertension was 
described in only one patient, who developed acute renal failure associated with 
microangiopathic hemolytic anemia, requiring dialysis and progressing to end stage renal 
disease [Nochy et al., 1999]. It is considered that hypertension represents the most common 
feature of antiphospholipid syndrome nephropathy. The intrarenal vascular lesions 
generate systemic hypertension, which may worsen these lesions. Appearance of 
hypertension in a patient diagnosed with primary antiphospholipid syndrome may reveal 
the development of nephropathy associated with this disorder. Therefore, the patient with 
antiphospholipid syndrome who develops hypertension must be extensively investigated, 
including renal biopsy, irrespective of the presence of proteinuria, hematuria or decreased 
glomerular rate filtration [Nochy et al., 1999; Tektonidou, 2009; Sinico et al., 2010]. 
In his study, Nochy identified renal insufficiency in 87% of patients. It was mild in the most 
patients (mean value of serum creatinine 1.64 mg/dl), being associated with proteinuria and 
hematuria. End stage renal disease appeared only in one patient [Nochy et al., 1999]. 
Usually, proteinuria is mild (< 1 g/24 hours). In 25% of patients, it becomes in nephrotic 
range. Renal lesions in antiphospholipid syndrome nephropathy were described by many 
authors [Nochy et al., 1999; Griffiths et al., 2000; Tektonidou, 2009, Gigante et al., 2009]. 
Thrombotic microangiopathy represents the most characteristic lesion in this nephropathy 
[Amigo et al., 1992; Griffiths et al., 2000]. It is defined by the presence of fibrin thrombi in 
glomerular capillaries and in intrarenal vessels, without inflammatory cells or immune 
deposits. The most frequently affected vessels are: preglomerular arterioles, small 
interlobular arteries, glomerular capillaries. Complete noninflammatory vascular occlusions 
by intraluminally, subendothelial, and medial accumulation of fragmented erythrocytes, 
leucocytes and eosinophilic fibrinoid material may be observed. Old lesions are associated 
with recanalization thrombi. Immunofluorescence shows that the fibrin is the main 
constituent of these thrombi. Vasculitis was absent in many performed studies [Nochy et al., 
1999; Gigante et al., 2009]. Arteriosclerosis lesions consist of fibrous intimal thickening and 
reduction of arcuate and interlobular arteries lumen. Arteriolar hyalinosis and 
arteriolosclerosis are identified, too [Gigante et al., 2009]. Fibrous intimal hyperplasia is 
characterized by intense myofibroblastic intimal cellular proliferation, which determines 
thickening of intima and tortuosity of interlobular arteries and their branches. The intima 
seems to be much more cellular than it observed in aging arteriosclerosis. Media may be 
atrophic and fibrous, or hypertrophic (hypertrophic myocites). Reduced lumen is caused by 
fibrous thickening of intima or recanalization after thrombosis. The organized thrombi may 
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be seen. Small interstitial arteries present fibrocellular and fibrous occlusions [Nochy et al., 
1999; Gigante et al., 2009]. Focal cortical atrophy is placed in the superficial zones of the 
subcapsular cortex, near the renal capsule, which presents a contour depression. It is 
identified a sharp border between focal cortical atrophy and the normal kidney cortex. This 
lesion is considered to be very specific for the nephropathy associated with 
antiphospholipid syndrome. In the regions of focal cortical atrophy, some histological 
characteristics were described. Glomeruli present two patterns, which may be seen in the 
same biopsy. Some of them are small and sclerotic, but others are voluminous and 
pseudocystic. Dense interstitial fibrosis, tubular atrophy, thyroidization and fibrous intimal 
hyperplasia of the vessels are other histological features. The arterioles are occluded by 
fibrin thrombi or by fibrous tissue [Gigante et al., 2009]. The main histological features of 
glomeruli, tubules, interstitium, and intrarenal vessels are presented in table 2. 
 
Glomeruli Light microscopy 
 enlarged 
 normal glomerular cellularity 
 increased number of capillary loops 
 diffusely thickened of capillary walls 
 double contours of glomerular basement membrane (the outer contour is 
wrinkled with redundant folds) 
 cellular interposition between the glomerular basement membrane and 
endothelial cells 
 central mesangiolysis  
Immunofluorescence 
 negative 
Electron microscopy 
 lucent flocculent material between the endothelial cells and glomerular 
basement membrane  
Tubules  atrophied 
 thyroidization 
Interstitium  fibrosis 
Intrarenal vessels Grade 1 
 endothelial swelling 
 mild fibrous arterial intimal thickening 
and/or 
 mild patchy arteriolar hyalinosis 
Grade 2 
 moderate fibrous arterial intimal thickening 
or 
 moderate arteriolar hyalinosis 
Grade 3 
 severe occlusive intimal thickening 
 thrombosis 
Table 2. The main histological features in antiphospholipid syndrome nephropathy 
Griffiths et al. and D'Cruz et al. showed that the redundant, wrinkled segments of glomerular 
basement membrane and duplicate straighter thin membrane represents pathognomonic 
findings of antiphospholipid syndrome nephropathy [Griffiths et al., 2000; D'Cruz, 2009]. The 
www.intechopen.com
 
The Kidney in Antiphospholipid Syndrome 
 
131 
reports of Asherson, Bucciarelli et al., and Erkan et al. demonstrated that the kidney is one of 
the most frequently affected organs in catastrophic antiphospholipid syndrome [Asherson, 
1992; Erkan et al., 2003; Bucciarelli et al., 2006]. Because of this form of antiphospholipid 
syndrome is very rare (less than 1% of antiphospholipid syndrome cases), there are few data 
about renal histological characteristics. Some cases of catastrophic antiphospholipid syndrome 
with renal involvement, in which renal biopsies were performed, showed fibrin thrombi in 
arteries and glomerular capillaries. Chronic vascular lesions were only rare identified 
[Tektonidou et al., 2008; Tektonidou, 2009]. The efficacy of anticoagulants in the treatment of 
antiphospholipid syndrome nephropathy wasn't evaluated. Based on the intrarenal 
thrombotic lesions which characterized this nephropathy, oral anticoagulation seems to be an 
acceptable therapy, even the long-term effects on renal function are not known, yet [Sinico et 
al., 2010]. Korkmaz et al. reported that proteinuria was reduced and renal function improved 
after a combined treatment with immunosuppressive, anticoagulants, calcium channel 
blockers and angiotensin-converting enzyme inhibitors [Korkmaz et al., 2003]. 
5. Renal vein thrombosis 
Asherson et al. described for the first time renal vein thrombosis in two patients with 
proliferative lupus nephritis and positive LA [Asherson et al., 1993]. D'Cruz suggested that 
the aPL had an important role in the development of renal vein thrombosis [D'Cruz, 2005]. 
This lesion is more frequently among the patients with antiphospholipid syndrome and 
systemic lupus erythematosus than in patients without lupus. Nephrotic syndrome is the 
main clinical manifestation. Because of this situation, it is indicated that any patient with 
antiphospholipid syndrome who develops sudden nephrotic range proteinuria should be 
evaluated by imagistic methods the renal veins (fig. 2). 
 
Fig. 2. Renal vein thrombosis (Duplex ultrasonography of the right renal vein) 
Renal failure is a consequence of bilateral vein thrombosis. Anticoagulation represents the 
therapeutic key of this renal complication in antiphospholipid syndrome [Nochy et al., 2002; 
Tektonidou, 2009]. 
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6. End-stage renal disease/renal transplantation 
In patients undergoing hemodialysis for end-stage renal disease, it was reported a high 
prevalence of aPL. In a group of 97 patients with end-stage renal disease treated by 
hemodialysis, Brunet et al. identified LA in 16.5% of them, and aCL in 15.5% [Brunet et al., 
1995]. No relations between aPL and sex, age, duration of dialysis, hepatitis viruses B, C were 
identified [Tektonidou, 2009]. Some studies established a relationship between aPL and 
vascular access thrombosis, especially in patients with LA [Lesar et al., 1999; Haviv, 2000]. 
Among the patients with renal transplant, it was identified a high incidence of aPL 
[Tektonidou, 2009]. The risk for vascular thrombosis and renal graft failure was increased in 
these patients [Andrassy et al., 2004]. Ducloux et al. identified aPL in 28% of transplant 
recipients; among them, 18% developed thrombotic complications [Ducloux et al., 1999]. The 
risk of thrombotic complications was greater in aPL-positive patients with systemic lupus 
erythematosus [Moroni et al., 2005]. The role of anticoagulant therapy in aPL-positive renal 
transplanted patients remains controversial, and prospective studies are necessary in order to 
establish the best modality for prevention of thrombotic complications [Tektonidou, 2009].  
7. Antiphospholipid antibodies and systemic lupus erythematosus 
Antiphospholipid antibodies are identified in approximately 30-40% of patients with 
systemic lupus erythematosus (SLE) [Tektonidou, 2009], but antiphospholipid syndrome 
appeared in 30% of cases [Tektonidou et al., 2004]. Hypertension from mild to malignant, 
hematuria, proteinuria from mild to nephrotic range, acute or chronic renal failure are the 
main clinical and laboratory findings in patients with SLE and aPL [Kleinknecht et al., 1989]. 
But all these findings may be the consequence of antiphospholipid syndrome nephropathy 
without any lesion of lupus nephropathy, or lupus nephropathy alone, or lupus 
nephropathy associated with antiphospholipid nephropathy. In these conditions, renal 
biopsy is a mandatory procedure for all the patients with SLE and aPL, who develop renal 
disease. This procedure provides useful data for prognosis, guiding the therapy [Asherson, 
Klumb, 2008; Gigante et al., 2009]. 
The most common renal lesion in patients with SLE and aPL is thrombotic microangiopathy. 
These patients present mainly arterial hypertension. Acute thrombotic lesions have a 
progressive evolution to chronic proliferative, obstructive, and fibrotic forms (focal cortical 
atrophy, fibrous intimal hyperplasia of arterioles, arteriolar occlusions, and sclerotic 
lesions). Chronic lesions are correlated with raised levels of serum creatinine. The patients 
who present hypertension and raised levels of serum creatinine at the time of kidney biopsy 
have an accelerated evolution to end stage renal disease [Tektonidou et al., 2004]. 
Antiphospholipid syndrome may occur in any class of lupus nephropathy. The studies 
didn't demonstrate a correlation between the class of lupus nephropathy and the presence of 
antiphospholipid syndrome. It was no correlation between antiphospholipid syndrome and 
activity or chronicity index scores, or between aPL titers and anti-DNAds antibodies or 
serum complement levels [Fofi et al., 2001; Hill, Nochy, 2007]. 
In patients with any class of lupus nephropathy and aCL, renal biopsies showed a greater 
degree of sclerosis, crescent formation and glomerular necrosis. Moss and Isenberg 
demonstrated that in classes III and IV of lupus nephropathy the presence of aPL is 
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associated with thrombosis of glomerular capillaries, which may evolve to glomerular 
sclerosis [Moss, Isenberg, 2001]. Moroni et al. identified a strong association between aPL 
and class V of lupus nephropathy [Moroni et al., 2004].  
Positivity for antinucleosome antibodies at the time of antiphospholipid syndrome 
diagnosis may predict the subsequent development of SLE [Hill, Nochy, 2007]. Andreoli et 
al. reported a high frequency of antinucleosome antibodies in patients with 
antiphospholipid syndrome. Some of these patients developed SLE during the period of 
follow-up [Andreoli et al., 2008]. Antiphospholipid syndrome patients with membranous 
nephropathy or proliferative glomerulonephritis represent a group with high risk for 
developing SLE. Thus, the antiphospholipid syndrome patients with antinucleosome 
antibodies, membranous nephropathy or proliferative glomerulonephritis need a careful 
monitoring in order to detect the appearance of SLE [Hill, Nochy, 2007; Andreoli et al., 
2008]. On the other hand, Loizou et al. demonstrated that in patients with SLE, the 
association between aCL, high titers of anti-DNAds and anti-C1q antibodies is very specific 
for renal involvement [Loizou et al., 2000].These patients benefit by the association between 
anticoagulants, steroid and immunosuppressive therapy. Immunoadsorption treatment was 
used in order to reduce the antibodies levels [Hauser et al., 2005]. 
8. Glomerulonephritis and antiphospholipid syndrome 
Beside the renal lesions which define the antiphospholipid syndrome nephropathy, in 
patients with primary antiphospholipid syndrome, kidney biopsies revealed glomerular 
lesions. Fakhouri et al. identified glomerular lesions in 9 from 29 patients with 
antiphospholipid syndrome. They were represented by: membranous glomerulonephritis 
(three cases), pauci-immune crescentic glomerulonephritis (one case), glomerulonephritis 
with C3 mesangial deposits (two cases), minimal change disease/focal segmental 
glomerulosclerosis (three cases). The patients from this study presented proteinuria, even in 
nephrotic range, hematuria, decreased of renal function. They were treated with 
antihypertensive (six cases), anticoagulants (five cases), steroids (four cases), and 
antiplatelets drugs (three cases). At last follow-up, renal function was stabilized in seven of 
these patients [Fakhouri et al., 2003].  
Membranous nephropathy was the most described glomerulonephritis among the patients 
with antiphospholipid syndrome [Dorel et al., 2000; Fakhouri et al., 2003].  
Crescentic glomerulonephritis may be present in patients with primary antiphospholipid 
syndrome. Cisternas et al. and Dede et al. reported two cases of crescentic 
glomerulonephritis who developed in patients with primary antiphospholipid syndrome 
[Cisternas et al., 2000, Dede et al., 2008]. Cisternas et al. showed an association between 
catastrophic antiphospholipid syndrome and crescentic glomerulonephritis with renal 
failure [Cisternas et al., 2000]. Dede et al. described the case of a young female with pauci-
immune glomerulonephritis, p-ANCA positive that had a favourable evolution under the 
therapy consisted of steroids and cyclophosphamide. After 3 months of follow-up, the 
patient was in clinical and laboratory remission [Dede et al., 2008].  
Abdalla et al. reported a case of membrano-proliferative glomerulonephritis with no 
evidence of thrombotic microangiopathy or systemic lupus erythematosus. The authors 
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sustained the role of immune deposits in pathogenesis of proliferative glomerulonephritis 
associated with primary antiphospholipid syndrome [Abdalla et al., 2006]. 
Another type of glomerular lesion was identified by Bhowmik et al. They described a case of 
focal segmental glomerulosclerosis who had a favourable course under the treatment with 
aspirin, heparin (during pregnancy), then angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers and steroids [Bhowmik et al., 2005]. 
The therapy of glomerulonephritis associated with antiphospholipid syndrome is based on 
steroids, immunosuppressive drugs, angiotensin-converting enzyme inhibitors, angiotensin 
receptor blockers, aspirin or anticoagulants  [Dorel et al., 2000; Fakhouri et al., 2003; 
Bhowmik et al., 2005; Abdalla et al., 2006;  Dede et al., 2008]. 
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